Publication & Citation Trends
Publications
36 total
First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies PDF
Cited by 4
OpenAlex
23ME-00610, a genetically informed, first-in-class antibody targeting CD200R1 to enhance antitumor T cell function PDF
Cited by 15
OpenAlex
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial
Cited by 21
OpenAlex
An LC-MS/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: Development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer
Cited by 15
OpenAlex
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks PDF
Cited by 59
OpenAlex
2490. Longer-Term Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Adults Living With HIV and End-Stage Renal Disease on Chronic Hemodialysis PDF
Cited by 5
OpenAlex
The determination of human peripheral blood mononuclear cell counts using a genomic DNA standard and application in tenofovir diphosphate quantitation
Cited by 5
OpenAlex
Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial
Cited by 33
OpenAlex
Research Topics
Cancer Immunotherapy and Biomarkers
(17)
Immune Cell Function and Interaction
(14)
Immunotherapy and Immune Responses
(13)
HIV/AIDS drug development and treatment
(9)
HIV/AIDS Research and Interventions
(5)
Affiliations
University of California, San Francisco
San Francisco Foundation
Rapt Therapeutics (United States)
23andMe (United States)
Soleno Therapeutics (United States)